Research Project
Grant-in-Aid for Challenging Exploratory Research
We investigated the serum levels of cystatin C in the subjects with sporadic ALS, both cross-sectionally and longitudinally, to clarify whether serum cystatin C is a potential biomarker reflecting the severity of motor dysfunction and predicting prognosis of this disease. The results were compared with those with healthy controls (HC) and spinal and bulbar muscular atrophy (SBMA). Baseline levels of serum cystatin C in the subjects with ALS were significantly higher than those of HC and SBMA. As for the relationship between disease severity, a strong correlation was found between baseline levels of serum cystatin C and ALSFRS-R in the subjects with ALS. Furthermore, baseline levels of serum cystatin C were correlated with the 24-week change of %FVC and that of appendicular lean soft tissue mass, as an index of skeletal muscle mass, in ALS. In conclusion, serum cystatin C may be a potential biomarker which reflects the disease progression of ALS.
All 2016 2015
All Journal Article (3 results) (of which Peer Reviewed: 3 results, Open Access: 2 results, Acknowledgement Compliant: 1 results) Presentation (4 results) (of which Int'l Joint Research: 1 results, Invited: 1 results)
Neurobiology of Aging
Volume: 39 Pages: 219-219
10.1016/j.neurobiolaging.2015.11.030
J Neurosci Res.
Volume: 93 Issue: 10 Pages: 1552-1566
10.1002/jnr.23619
Nat Commun
Volume: 6 Issue: 1 Pages: 7098-7098
10.1038/ncomms8098